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Background: Bladder cancer is the most common malignancy in urinary system and the ninth most common
malignancy in the world. MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression by targeted
repression of transcription and translation and play essential roles during cancer development. We investigated the
expression of miR-135a in bladder cancer and explored its bio-function during bladder cancer progression.
Methods: The expression of miR-135a in bladder cancer cells and tissues are performed by using Real-time PCR
assay. Cell viability assay (MTT assay), colony formation assay, anchorage-independent growth ability assay and
Bromodeoxyuridine labeling and immunofluorescence (BrdUrd) assay are used to examine cell proliferative capacity
and tumorigenicity. Flow cytometry analysis is used to determine cell cycle progression. The expressions of p21, p27,
CyclinD1, Ki67, PHLPP2 and FOXO1 are measured by Western blotting assay. Luciferase assay is used to confirm
whether FOXO1 is the direct target of miR-135a.
Results: miR-135a is upregulated in bladder cancer cells and tissues. Enforced expression of miR-135a promotes
bladder cancer cells proliferation, whereas inhibition of miR-135a reverses the function. Furthermore, for the first
time we demonstrated PHLPP2 and FOXO1 are direct targets of miR-135a and transcriptionally down-regulated by
miR-135a. Suppression of PHLPP2 or FOXO1 by miR-135a, consisted with dysregulation of p21, p27, Cyclin D1 and
Ki67, play important roles in bladder cancer progression.
Conclusion: Our study demonstrates that miR-135a promotes cell proliferation in bladder cancer by targeting
PHLPP2 and FOXO1, and is performed as an onco-miR.
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Bladder cancer is the most common malignancy involv-
ing the urinary system and more than 350,000 new cases
of bladder cancer are diagnosed globally each year [1,2].
Bladder cancer is the fourth most common cancer in
males and ninth most common in females; it is the ninth
most common malignancy overall [2,3]. In middle-aged
and elderly men, bladder cancer is the second most
prevalent malignancy after prostate cancer [4]. Due to* Correspondence: mxpzc1979@163.com; chenjunxindoctor@163.com
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unless otherwise stated.the high occurrence and mortality, accurate and effective
diagnostic and therapeutic methods for bladder cancer,
based on a comprehensive understanding of bladder can-
cer progression, are urgently required. Increasing attention
is being paid to the biological behavior and mechanisms of
bladder cancer development.
The PHLPP (Pleckstrin Homology (PH) domain leucine-
rich repeat protein phosphatase) isoforms comprises three
members, PHLPP1α, PHLPP1β, and PHLPP2, which are
essential regulators of Akt serine-threonine kinases [5-7].
PHLPP2, as one member of PHLPP, attenuate the ampli-
tude of Akt signaling by dephosphorylate and inactivate
Akt1 and Akt3 [6]. Moreover, PHLPP has been found to
act as a tumor suppressor in several types of cancer due tois is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer cells [5,7]. FOXO1 belongs to subfamily of the
forkhead transcription factors which are characterized
by a conserved forkhead DNA binding domain [8]. It
has been reported that FOXO transcription factors are
involved in various signaling pathway and modulate a
broad range of biochemical processes, such as cell cycle
progression, differentiation, DNA damage repair, and
apoptosis [8-11]. FOXO1 is known as a tumor suppres-
sor, and deregulation of FOXO1 is involved in a variety
of tumors [12-15]. As FOXO transcription factors are
downstream targets of the serine/threonine protein
kinase B (PKB)/Akt, the inhibition of FOXO1 is due to
high level activation of Akt or other kinases. Activited
Akt leads to FOXO1 phosphorylation, and results in
FOXO1 translocating from nucleus to cytoplasm, and
then being followed with ubiquitinatination and degrad-
ation. Since both PHLPP2 and FOXO1 are the negative
regulators of Akt signaling pathway, the regulatory
mechanism of these two regulators during bladder can-
cer progression arouses attention.
Multiple biomarkers have been identified, providing a
better understanding of the molecular mechanisms in-
volved in bladder carcinogenesis and tumor progression.
MicroRNAs (miRNAs), a class of endogenous, small
non-coding RNAs of 20–22 nucleotides, have been
shown to be dysregulated in various human cancers and
play important roles in cancer pathogenesis. MiRNAs
function by regulating a variety of target genes, through
binding with partially complementary sequences in the
3′-untranslated regions (3′-UTR) of targeted mRNAs
[16,17]. Increasing numbers of reports indicate that miR-
NAs can act as diagnostic or prognostic markers of blad-
der cancer [18-20]. Furthermore, miRNAs are involved
in the modulation of many biological processes of blad-
der cancers, including cell proliferation, apoptosis, cell
invasion and migration, and angiogenesis [21-26].
In the present study, miR-135a was found to be up-
regulated in bladder cancer cells and tissues, indicating
the potential function of miR-135a in bladder cancer
development. Ectopic expression of miR-135a in bladder
cancer cells led to the promotion of cell proliferation,
tumorigenicity and cell cycle regulation, while inhibition
of miR-135a suppressed the tumor proliferation and
tumorigenesis. Moreover, our study presented data indi-
cating that PHLPP2 and FOXO1 are direct targets of,
and downregulated by, miR-135a. Thus, miR-135a plays
essential role during the regulation of PHLPP2 and
FOXO1, followed with activation of Akt related pathway
in bladder cancer cells. Our present study suggested
that miR-135a promotes cell proliferation, tumorigen-
icity and cell cycle progression in bladder cells by acti-
vating Akt signaling pathway via targeting PHLPP2 and
FOXO1 mRNA and suppressing their expression.Materials and methods
Cell culture and tissue specimens
Human bladder cancer cells (EJ, T24, BIU87, SCaBER,
and 5637) were cultured in RPMI 1640 medium (Invi-
trogen, Carlsbad, CA, USA), supplemented with 10%
fetal bovine serum (HyClone, Logan, UT, USA), penicil-
lin and streptomycin (100 IU/ml) at 37°C under a 5%
CO2 atmosphere in a humidified incubator. The pri-
mary cultures of normal bladder epithelial cells and
bladder cancer cells established from fresh specimens of
the normal bladder tissues and bladder cancer tissues
respectively, had been histopathologically diagnosed and
verified by experienced pathologists. The bladder biopsy
was cut into two pieces; first piece would be used for
establishing normal bladder epithelial cells. Second
piece would be examined whether it is noncancerous
bladder tissue by routine histopathological analysis,
which confirms that the bladder epithelial cells estab-
lished from above-mentioned first piece, are normal
bladder epithelial cells (shown as NC). In brief, surgical
specimens from normal bladder were promptly re-
moved and transported aseptically in Hanks’ solution
(Invitrogen) with 100 units/ml penicillin, and 100 μg/ml
streptomycin (Invitrogen) and 5 μg/ml gentamicin
(Invitrogen). The tissue specimens were incubated with
1.5 units/ml dispase (Roche Molecular Biochemicals) at
4°C overnight, and the epithelium was dissected away
and incubated with trypsin (Invitrogen). The reaction
was stopped with soybean trypsin inhibitor (Sigma,
Saint Louis, MI) and centrifuged. The pellet was resus-
pended in keratinocyte-SFM medium (KSFM) (Invitro-
gen) supplemented with 40 μg/ml bovine pituitary
extract (Invitrogen), 1.0 ng/ml EGF (Invitrogen), 100
units/ml penicillin, 100 μg/ml streptomycin (Invitro-
gen), 5 μg/ml gentamycin, and 100 units/ml nyastatin
(Invitrogen). Normal bladder cells were grown at 37°C
and 5% CO2 with KSFM, with 40 μg/ml bovine pituitary
extract, 1.0 ng/ml EGF, 100 units/ml penicillin, and
100 μg/ml streptomycin) [27,28].
Bladder tumor tissues and adjacent non-tumor bladder
tissues were collected from radical cystectomy and diag-
nosed histopathologically at the Department of Urology,
the First Affiliated Hospital, Sun Yat-Sen University (the
pathology of the tumor was: the sample #1, #2, #3 and
#5 are of grade III, the sample #4 and #6 are of grade II,
and the sample #7 is of grade I and all the samples were
originated as urothelial cancers). None of patients under-
went chemotherapy, radiotherapy or adjuvant treatment
before surgery. All samples were obtained with written
informed consent and approved by the Institutional
Research Ethics Committee of the First Affiliated Hospital
of Sun Yat-Sen University. The tissues and the matched
adjacent non-cancerous bladder tissues were frozen and
stored in liquid nitrogen for further use.
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The miR-135a expression plasmid, pMSCV-miR-135a,
was generated by cloning the genomic pre-miR-135a
gene into the retroviral transfer plasmid pMSCV-puro
(Clontech Laboratories Inc., Mountain View, CA, USA).
Stable cell lines expressing miR-135a were established
via retroviral infection according to a previously re-
ported protocol [29] and stably transduced cells were
selected by treatment with 1.5 μg/ml puromycin for
10 days beginning at 48 h after infection. The expres-
sion level of stably engineered cell lines was examined
by real-time PCR.
RNA extraction, reverse transcription (RT) and real-time PCR
Total cellular RNA was extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the proto-
col provided by the manufacturer and used to synthesize
cDNA with specific stem-loop primers and the TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosys-
tems; Foster City, CA, USA). Expression of miRNAs
was analyzed using the TaqMan MicroRNA Assay kit
(Applied Biosystems). Gene expression levels were
quantified using the 7500 Fast Real-Time Sequence
detection system software (Applied Biosystems). Gene
expression was defined based on the threshold cycle
(Ct) normalized to that of the housekeeping gene
GAPDH as the control (GAPDH forward primer, 5′-
GACTCATGACCACAGTCCATGC-3′; reverse primer,
3′-AGAGGCAGGGATGAT GTTCTG-5′), and calcu-
lated as 2-[(Ct of p21, p27, CyclinD1, Ki67) – (Ct of GAPDH)]. The
relative expression levels of miRNA were calculated as
2-[(Ct of miR-135a) – (Ct of U6)]. Small nuclear RNA U6 was
used for normalization, and the primers for miRNA were
purchased from RiboBio (RiboBio Co. Ltd, Guangzhou,
Guangdong, China).
PCR amplification of genes was carried out using
the following thermal conditions: 95°C for 30 s
followed by 40 cycles of 95°C for 5 s and 60°C for
30 s. The PCR conditions for amplification of miR-
135a were: 95°C for 20 s, followed by 40 cycles of
95°C for 10 s and 60°C for 20 s, with a final incuba-
tion at 70°C for 5 s.
The primers selected were as follows:
p21 forward: 5′-CATGGGTTCTGACGGACAT -3′,
p21 reverse: 5′- AGTCAGTTCCTTGTGGAGCC -3′;
p27 forward: 5′- TGCAACCGACGATTCTTCTACTC
AA -3′,
p27 reverse: 5′- CAAGCAGTGATGTATCTGATAAAC
AAGGA-3′.
Cyclin D1 forward: 5′-AACTACCTGGACCGCTTCCT -3′,
Cyclin D1 reverse: 5′-CCACTT GAGCTTGTTCACCA-3′.
Ki67 forward: 5′- AGGACTTTGTGCTCTGTAACC -3′,
Ki67 reverse: 5′- CTCTTTTGGCTTCCATTTCTTC -3′.Western blotting assay
Total protein was extracted from whole cells by a previ-
ously described procedure. Lysate protein (20 μg) for
Western blotting was separated by SDS-PAGE and elec-
troblotted onto a PVDF membrane (Bio-Rad Laboratories,
Hercules, CA, USA). The membranes were probed with
polyclonal rabbit antibodies against anti-FOXO1, anti-p21,
anti-p27, anti-CyclinD1, and anti-Ki67 (1:1,000; Cell
Signaling, Danvers, MA, USA). The membranes were
stripped and re-probed with an anti-α-tubulin mouse
monoclonal antibody (1:1,000; Cell Signaling) as a load-
ing control.
Oligonucleotides, siRNA and transfection
The miR-135a mimic (50 nM), miR-135a inhibitor (100
nM; miR-inhibitor is a commercial product from a
professional bio-company “RiboBio” (RiboBio Co. Ltd,
Guangzhou, Guangdong, China), is a LNA/OMe modi-
fied antisense oligonucleotide designed specifically to
bind to and inhibit endogenous miR molecule with
rarely off-target effect), and negative control (NC) were
purchased from RiboBio. For depletion of FOXO1, the
siRNA (50 nM) was synthesized and purified by Ribo-
Bio. The PHLPP2 siRNA sequence: 5′-CCTAAGTGGC
AACAAGCTT-3′; FOXO1 siRNA sequence used were:
5′-GCA AAGAUGGCCUCUACUU-3′; Transfections
with oligonucleotides and siRNA were performed using
the Lipofectamine 2000 reagent (Invitrogen) according
to the manufacturer’s instructions.
Cell viability assay
Cells were seeded in 96-well plates at 2 × 103 per well.
At the indicated time-points, 100 μl MTT (0.5 mg/ml,
Sigma, Saint Louis, MO, USA) was added to each well
and cells were incubated for 4 h at 37°C, followed by
removal of the culture medium and addition of 150 μl
DMSO (Sigma). The absorbance was measured at 570 nm,
with 655 nm as the reference wavelength. All experiments
were performed in triplicate.
Colony formation assay
Cells (0.5 × 103 cells per well) were seeded into 6-well
plates and cultured for 14 days. Cells were subsequently
fixed with glutaraldehyde (6.0% v/v, Sigma), and stained
with crystal violet (0.5% w/v, Sigma) for 5 min. The
number of colonies formed was counted in 10 different
fields of vision and the mean value was calculated. The
experiment was performed independently three times
for each cell line.
Anchorage-independent growth ability assay
An agar layer, comprising a 0.6% complete medium agar
mixture, was prepared in a 6 cm tissue culture dish. Sub-
sequently, 1.5 × 103 cells, suspended in 2 ml complete
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agar layer. The cells were incubated at 37°C for 2 weeks
to allow for growth of colonies. Colonies greater than
0.1 mm in diameter were counted. The experiment was
performed independently three times for each cell line.Flow cytometric cell cycle analysis
Cells (1 × 106) were harvested and fixed in 75% ice-cold
ethanol. Before cell cycle analysis, cells were treated with
bovine pancreatic RNase (2 μg/ml; Sigma) at 37°C for
30 min, followed by incubation in propidium iodide
(20 μg/ml; Sigma) for 20 min. Cell cycle analysis was per-
formed using the BD LSRII Flow Cytometry System with
FACSDiva software (BD Bioscience, Franklin Lakes, USA).
The data were analyzed with the ModFit LT software
package and the cell cycle distribution was shown as the
percentage of cells in the G1, S, and G2 populations.Bromodeoxyuridine labeling and immunofluorescence
Cells (7 × 104) grown on coverslips were incubated with
bromodeoxyuridine (BrdUrd) for 1 h and stained with
anti-BrdUrd antibody (Upstate, Temecula, CA) according
to the manufacturer’s instructions. Gray level images were
acquired under a laser scanning microscope (Axioskop 2
plus, Carl Zeiss Co. Ltd., Jena, Germany).Luciferase assay
The luciferase miRNA target expression vector pGL3
was used for 3′-UTR luciferase assays (Promega, Madi-
son, WI, USA). The primer sequences for the wild-type
3′UTR (334 bp) were: Forward, 5′-CGGGGTACCA
GTTGGCCTCTCCTTGAGGT 3′; Reverse, 5′-GAA-
GATCTGGCTGACAAGACTTAACTCAA-3′. For the
mutant 3′UTR, QuikChange® Site-Directed Mutagen-
esis Kit (Agilent Technologies, Inc., CA, USA) was used





ase assays, cells (5 × 104) were plated in a 24-well plate
and incubated for 24 h prior to transfection. Firefly
luciferase constructs containing the 3′UTR (or 3′UTR-
mutant) of the potential miR-135a target (100 ng), pRL-TK
Renilla luciferase normalization control (1 ng; Promega),
miRNA mimic, inhibitor or negative control were cotrans-
fected using Lipofectamine 2000 (Invitrogen). Lysates
were collected 48 h after transfection and measured
using a Dual-Luciferase Reporter System (Promega) ac-
cording to the manufacturer protocol. Three independ-
ent experiments were performed and the data were
presented as the mean ± SD.Statistical analysis
Student’s t-test (using a two-tailed paired t-test) was
used to evaluate the significant difference of two groups
of data in all the pertinent experiments. All data were
expressed as the mean ± standard deviation (SD) for
three independent experiments. A P-value < 0.05 was
regarded as statistically significant.
Results
MiR-135a expression is elevated in bladder cancer
the expression of miR-135a was exmined by real-time
RT-PCR in bladder cancer. MiR-135a was found to be
markedly upregulated in bladder cancer cells, including
primary cultures of bladder cancer tissues and bladder
cancer cell lines, EJ, T24, BIU87, SCaBER, and 5637,
compared with normal bladder epithelial cells (primary
cultures of normal bladder tissues) (Figure 1A). In order
to further verify the expression pattern of miR-135a in
human bladder cancer tissues, we examined and com-
pared the expression levels of miR-135a in seven pairs of
human bladder cancer tissues and adjacent non-tumor
tissues. The results showed that the relative expression
of miR-135a in bladder cancer tissues was significantly
higher than that of their matched adjacent normal tis-
sues (n = 7, r = 0.896, P = 0.006; Figure 1B). These data
suggested that miR-135a expression was elevated in
bladder cancer, indicating a putative tumor-promoter
function of miR-135a in bladder cancer.
MiR-135a promotes bladder cancer cell proliferation and
cell cycle progression
To determine the tumor-promoter function of miR-135a
in bladder cancer progression, T24, 5637 and BIU87
cells stably overexpressing miR-135a were established
for further investigations. An MTT assay showed that
ectopic expression of miR-135a significantly increased
the growth rate of bladder cells (Figure 2A, Additional
file 1: Figure S1A). Meanwhile, colony formation assays
showed that overexpression of miR-135a enhanced the
proliferation of bladder cancer cells, and colonies were
much larger in bladder cancer cells stably overexpressing
miR-135a (Figure 2B, Additional file 1: Figure S1B and
Additional file 2: Figure S2A). Additionally, an anchorage-
independent growth assay revealed that bladder cells
stably overexpressing miR-135a showed more and larger-
sized colonies than control cells (Figure 2C, Additional
file 1: Figure S1C and Additional file 2: Figure S2B). The
cell cycle analysis of T24 and 5637 cells by flow cytome-
try showed a significant decrease in the percentage of
cells in G1/G0 phase and an increase in the percentage of
cells in S phase (Figure 2D). The level of DNA synthesis,
when examined by BrdUrd incorporation assay, was
significantly elevated in miR-135a overexpressing T24 and
5637 cells, whereas the control cells displayed relatively
Figure 1 Expression of miR-135a is elevated in bladder cancer cells. A. Real-time PCR analysis of miR-135a expression in bladder cancer cells,
including primary culture cells of bladder cancer tissues (shown as T#1, T#2, T#3) and bladder cancer cell lines, EJ, T24, BIU87, SCaBER, and 5637,
compared to normal bladder cells as controls. The normal control for bladder cancer cell lines are primary cultures of normal bladder epithelial
cells established from fresh specimens of normal bladder tissues (shown as NC #1, #2, #3). B. The expression of miR-135a was examined in seven
pairs of cancerous tissues (T) and their adjacent non-cancerous bladder tissues (ANT). The average miR-135a expression was normalized using U6
expression. Bars represent the mean ± SD of three independent experiments. **P <0.01, *P <0.05.
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results indicated that overexpression of miR-135a pro-
moted the proliferation, tumorigenicity and cell cycle
progression of bladder cancer cells in vitro.
Inhibition of miR-135a suppresses proliferative capacity
of bladder cancer cells
Loss-of-function studies using a miR-135a inhibitor were
performed to further confirm whether inhibition of miR-
135a reduces bladder cancer cell proliferation. MTT and
colony formation assays showed that suppression of
miR-135a significantly decreased the proliferative cap-
acity of T24 and 5637 cells transfected with the miR-
135a inhibitor compared with that of NC transfected
cells (Figure 3A and B). The anchorage-independent
growth assay revealed that suppression of miR-135a led
to fewer and smaller colonies than the control cells
(Figure 3C). Flow cytometry showed a significant in-
crease in the percentage of cells in G1/G0 phase and a
decrease in the percentage of cells in S phase in cells
transfected with the miR-135a inhibitor compared with
NC transfected cells (Figure 3D). BrdUrd incorporation
assays showed that the level of DNA synthesis was
reduced by inhibition of miR-135a (Figure 3E). These
results suggested that downregulation of miR-135a re-
duces the proliferation and tumorigenicity of bladder
cancer cells.
MiR-135a decreases expression of the cell cycle inhibitors
p21Cip1 and p27Kip1 and increases expression of cell cycle
regulator Cyclin D1
As miR-135a promoted cell proliferation, we further in-
vestigated the effect of miR-135a on the expression of
the genes which regulate cell cycle and proliferation,
including p21Cip1, p27Kip1 and Cyclin D1. Compared to NC
transfected cells, p21Cip1 and p27Kip1 were downregulatedand Cyclin D1 was upregulated in miR-135a-transfected
cells, while p21Cip1 and p27Kip1 were upregulated and
Cyclin D1 was downregulated in miR-135a-inhibitor-
transfected cells (Figure 4A–C). Coincident with altered
expression of cell cycle regulators, the expression of Ki67,
a cellular marker for proliferation, was also significantly
increased in miR-135a-transfected cells, and decreased in
miR-135a-inhibitor-transfected cells (Figure 4A–C), which
further confirmed that miR-135a promoted the prolifera-
tion and cell cycle progression of bladder cancer cells.
PHLPP2 and FOXO1 are direct targets of miR-135a in
bladder cancer cells
To explore the molecular mechanism of miR-135a func-
tion in bladder cancer cells, the target of miR-135a was
predicted using the publicly available algorithms (TargetS-
can). PHLPP2 and FOXO1 were identified among the pu-
tative targets of miR-135a and the potential binding
sequence for miR-135a was identified within the 3′UTR of
PHLPP2 and FOXO1 (Figure 5A). The protein expression
of PHLPP2 and FOXO1 were further found to be de-
creased in the bladder cancer tissues, compared with that
of the normal bladder tissue, and miR-135a expression
in these bladder cancer tissues was inversely correlated
with the expression of PHLPP2 (r = −0.627, P < 0.05)
and FOXO1 (r =-0.712, P < 0.05) (Figure 5B). Meanwhile,
cells overexpressing miR-135a exhibited significantly lower
expression of PHLPP2 and FOXO1, while inhibition of
miR-135a led to higher PHLPP2 and FOXO1 expression
(Figure 5C). Co-transfection of miR-135a with the pGL3-
PHLPP2-3′UTR or pGL3-FOXO1-3′UTR luciferase re-
porter plasmid caused a remarkable decrease of luciferase
activity, whereas inhibition of miR-135a led to increased
luciferase activity (Figure 5D). However, luciferase activity
was not affected by miR-135a-mut transfection instead
of miR-135a;or pGL3-PHLPP2/FOXO1-3′UTR mutant
Figure 2 MiR-135a induces proliferation of bladder cancer cells. A. Effects of miR-135a on proliferation of the indicated cells, as analyzed by
MTT assays. B. Representative micrographs (left) and quantifications (right) of crystal violet stained colonies formed by the indicated cells. C. Effects of
ectopic miR-135a expression on the tumorigenicity of the indicated cells, as determined by anchorage-independent growth ability assays. D. Effects of
ectopic miR-135a expression on cell cycle progression of the indicated cells, as analyzed by flow cytometry. E. Representative micrographs (left) and
quantification (right) of the BrdUrd incorporation assay in the indicated cells. All these experiments were done with T24 and 5637 cells stably
overexpressing miR-135a or pMSCV-vector. Bars represent the mean ± SD of three independent experiments. *P <0.05.
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Figure 3 Inhibition of miR-135a suppresses the growth of bladder cancer cells. A. Effects of miR-135a inhibitor (shown as miR-135a-in) or
negative control (shown as NC) on the proliferation of bladder cancer cells, as analyzed by MTT assays. B. Representative micrographs (left) and
quantifications (right) of crystal violet stained colonies formed by the indicated cells. C. Effects of miR-135a inhibitor or negative control on the
tumorigenicity of the indicated cells, as determined by anchorage-independent growth ability assays. D. Effects of miR-135a inhibitor or negative
control on cell cycle progression of the indicated cells, as analyzed by flow cytometry. E. Representative micrographs (left) and quantification
(right) of the BrdUrd incorporation assay in the indicated cells. Bars represent the mean ± SD of three independent experiments. *P <0.05.
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Figure 4 MiR-135a modulates expression of cell cycle regulators, including p21Cip1, p27Kip1, Cyclin D1 and Ki67. A. Western blotting
analysis of p21Cip1, p27Kip1 , Cyclin D1 and Ki67 in indicated bladder cancer cells. α-Tubulin was used as a loading control. B. Real-time PCR
analysis of p21Cip1, p27Kip1, Cyclin D1 and Ki67 mRNA in bladder cancer cells transfected with miR-135a or NC. C. Real-time PCR analysis of p21Cip1,
p27Kip1, Cyclin D1 and Ki67 mRNA in bladder cancer cells transfected with the miR-135a inhibitor or NC. GAPDH was used as a loading control. Bars
represent the mean ± SD values of three independent experiments; *P < 0.05.
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and D; Additional file 3: Figure S3). Collectively, these
results suggested that miR-135a directly targets FOXO1
in bladder cancer cells.
Suppression of PHLPP2 or FOXO1 is essential for
miR-135a-induced cell proliferation in bladder cancer
To further confirm the importance effect of PHLPP2 or
FOXO1 suppression during miR-135a-induced bladder
cancer proliferation, a specific siRNA of PHLPP2 or
FOXO1 was used to suppress endogenous PHLPP2 or
FOXO1 expression, respectively (Figure 6A). The re-
sults of cell viability MTT and the colony formation assay
both indicated that suppression of PHLPP2 or FOXO1 in
cells transfected with miR-135a inhibitor dramatically in-
creased the proliferation of bladder cancer cells (Figure 6B
and C). Furthermore, the anchorage-independent growth
assay showed the similar results (Figure 6D). These results
suggested that silencing PHLPP2 and FOXO1 expression
in miR-135a-repressed cells could reverse the inhibitoryeffect of the miR-135a inhibitor on bladder cancer cells
proliferation. It is confirmed that miR-135a promotes
bladder cancer cells proliferation and tumorigenicity by
suppressing endogenous PHLPP2 and FOXO1 expres-
sion, and that PHLPP2 and FOXO1 suppression are
essential for miR-135a-mediated cell proliferation in
bladder cancer.
Discussion
Recently, the roles of miRNAs in the regulation of tumor
progression and development are attracting increasing
attention, with growing numbers of reports suggesting
that dysregulation of miRNAs contributes to certain
types of tumor progression. In the present study, we
found that miR-135a is significantly upregulated in blad-
der cancer cells and tissue, leading to increased bladder
cell proliferation and tumorigenicity. To explore the
mechanism of miR-135a-induced cell proliferation, we
investigated potential targets of miR-135a and found that
PHLPP2 and FOXO1 are directly targeted by miR-135a
Figure 5 (See legend on next page.)
Mao et al. Journal of Translational Medicine  (2015) 13:86 Page 9 of 13
(See figure on previous page.)
Figure 5 PHLPP2 and FOXO1 are potential targets of miR-135a. A. Sequence of PHLPP2- or FOXO1-3′UTR miR-135a binding seed region,
miR-135 and mutation of miR-135a (shown as miR-135a-mut). B. Upper: Western blotting analysis of PHLPP2 or FOXO1 in bladder cancer tissues,
compared with normal bladder tissue. α-Tubulin was used as a loading control. Lower: Real-time PCR analysis of miR-135a in bladder cancer
tissues, and the correlation between miR-135a and PHLPP2 or FOXO1 expression in bladder cancer tissues. C. The expression level of PHLPP2 or
FOXO1 protein in bladder cancer cells transfected with miR-135a or miR-135a inhibitor, respectively, compared with control cells (shown as NC), by
Western blotting analysis. α-Tubulin was used as a loading control. D. PHLPP2 or FOXO1 luciferase reporter activity in the indicated cells,
measured by luciferase assay. pRL-TK Renilla luciferase was used as the normalization control; Bars represents the mean ± SD of three independent
experiments. *P <0.05.
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bladder cancer. The negative regulation of PHLPP2 and
FOXO1 by miR-135a leads to dysregulation of phos-
phorylated Akt, p21, p27, CyclinD1 and Ki67, indicating
that miR-135a plays an essential role in bladder cancer
progression through Akt-mediated signaling (Figure 7).
As bladder cancer is the most common malignancy
involving the urinary system, much research has been
focused on the biological properties and progression of
bladder cancer. Based on the investigations of the bio-
logical and predictive functions of miRNAs in malignan-
cies, data are emerging that elucidate the effects of
miRNAs in bladder cancer. MiR-409-3p is reported to
be downregulated in bladder cancer and ectopic miR-
409-3p expression significantly reduced bladder cancer
cell migration and invasion [30]. MiR-23b was found to
act as a tumor suppressor in bladder cancer cells and
overexpression of miR-23b inhibited cell proliferation
and colony formation. Furthermore, miR-23b expression
is repressed in bladder cancer and is considered to be a
potential diagnostic and prognostic biomarker, with high
miR-23b expression being positively correlated with
higher overall survival of bladder cancer patients [31].
Liu et al. demonstrated that miR-135a contributes to the
development of portal vein tumor thrombus by promot-
ing invasion and metastasis in hepatocellular carcinoma
[32]. A miRNA-135a/b binding polymorphism, the SNP
rs2240688A > C in the 3′-untranslated region of CD133,
is considered to be a functional biomarker for the
prediction of risk and prognosis in lung cancer. It is
reported this SNP decreases risk and favorable progno-
sis in lung cancer by miRNA-135a/b-mediated reduc-
tion of CD133 expression [33]. Moreover, miR-135a
has been reported as a tumor-suppressive factor that
inhibits cancer cell proliferation by targeting c-MYC
in renal cell carcinoma [34]. All the previous studies
indicated that the function of miR-135a in tumor pro-
gression is complicated and segmentary, which needs
further investigation. The biological function of miR-
135a and its mechanism in bladder cancer develop-
ment has not been elucidated. Our study reveals for
the first time that miR-135a acts as an onco-miR and
promotes cell proliferation by reducing FOXO1 ex-
pression in bladder cancer.As has been reported, miRNAs play essential roles in
translational repression by targeting the 3′ untrans-
lated region (3′-UTR) of mRNAs in a sequence-
specific manner. MiR-490-5p inhibits proliferation of
bladder cancer cells by targeting c-Fos [21]. MiR-16 in-
hibits bladder cancer proliferation by targeting Cyclin
D1 [22]. C-Met is a direct target of miR-409-3p and
mediates the biological function of miR-409–3p in
bladder cancer [30]. MiR-23b inhibits cell proliferation
by post-transcriptionally regulating Zeb1 in bladder
cancer [31]. It has been reported that MiR-135a pro-
motes growth and invasion of colorectal cancer via
targeting and downregulating metastasis suppressor 1,
which is absent or reduced in cancer cells [35]. Wu
et al. found miR-135a targets JAK2 and reduces p-
STAT3 activation and cyclin D1 and Bcl-xL protein
expression, leading to inhibition of gastric cancer cell
proliferation [36]. Moreover, miR-135a is involved in
colorectal cancer pathogenesis via targeting and sup-
pressing adenomatous polyposis coli (APC) and in-
ducing downstream Wnt pathway activity [37]. In
addition, miRNA-135a was also found to promote
breast cancer cell migration and invasion by targeting
HOXA10 [38]. However, to date, the exact functions
and regulatory mechanisms of miR-135a in tumori-
genesis of bladder cancer remain largely unknown.
Currently, we demonstrate that PHLPP2 and FOXO1
are the direct targets of miR-135a and that silencing
PHLPP2 or FOXO1 plays a crucial role in miR-135a-
induced proliferation of bladder cancer cells. In addition,
as there are various targets that correlate with multiple
biological function of miR-135a in other tumors con-
firmed by previous studies, the potential function of miR-
135a on other bladder cancer biology might be of great
interest to explore.
PHLPP2 has been found function as tumor suppressor
in variety of malignancies. Loss of PHLPP expression, ei-
ther PHLPP1 or PHLPP2, in colorectal cancer was found
and overexpression of PHLPP inhibits proliferation of
colon cancer both in vitro and in vivo [39]. It has been
reported PHLPP2 is downregulated by miR-205 and
leads to stimulation of proliferation and angiogenesis in
non-small cell lung cancer cells [40]. Mei et al. found
that repression PHLPP2 plays crucial roles in miR-141-
Figure 6 MiR-135a promotes proliferation of bladder cancer cells by inhibiting PHLPP2 and FOXO1. A. The expression level of PHLPP2 or
FOXO1 in miR-135a-inhibitor transfected bladder cells that were transfected with PHLPP2- or FOXO1-siRNA, measured by Western blotting assays;
α-Tubulin served as the loading control. B. The growth rates in PHLPP2- or FOXO-silenced cells, measured by MTT assays. C. Representative
micrographs (left) and quantifications (right) of crystal violet stained colonies formed by the indicated cells. D. Representative images (left) and
quantifications (right) of colonies formed by the indicated cells determined by anchorage-independent growth assay. Bars represent the mean
± SD from three independent experiments. *P < 0.05.
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expression pattern and the regulatory mechanism of
PHLPP2 in bladder cancer remains unfolded. Herein, in
our present study, for the first time PHLPP2 was found
to be downregulated in bladder cancer and miR-135a wasfound to target and repress the expression of PHLPP2,
resulting the promotion of bladder cancer proliferation
and tumorigenesis. FOXO1, a member of the forkhead
box O (FOXO) subfamily of transcription factors, func-
tions as a tumor suppressor and regulates genes involved
Figure 7 The model of miR-135a-mediated Akt signaling
activation through down-regulation of PHLPP2 and FOXO1
that results in the promotion of bladder cancer cell proliferation
and tumorigenesis.
Mao et al. Journal of Translational Medicine  (2015) 13:86 Page 12 of 13in the apoptotic response, cell cycle checkpoints and
cellular metabolism. Accumulating data suggest that
FOXO1 is downregulated in various types of cancers.
However, the molecular mechanism resulting in aber-
rant expression of FOXO1 is poorly understood. Recent
evidence suggests that post-transcriptional regulation is
important for FOXO1 downregulation and the modula-
tion of its activity. It has been revealed that miR-96
plays an anti-apoptotic function in bladder and prostate
cancer through suppression of FOXO1 expression by
targeting its 3′UTR [23,42].
Moreover, PHLPP2 is found to be the suppressive
regulator of Akt signaling pathway [5-7] and FOXO1 is
known to be closely correlated with the phosphotidylino
sitide-3-kinase (PI3K)/AKT signaling pathway [14,15,43].
Further, activation of the PI3K/AKT signaling pathway
leads to FOXO1 phosphorylation, which results in
FOXO1 proteasomal degradation, and dysregulation
of Cyclin D1, Cyclin D2, and p21 levels and Cyclin-
Dependent Kinase-4 activity [43-45]. Consist with
previous studies, our results suggested that PHLPP2
and FOXO1 are both downregulated by miR-135a in
bladder cancer cells, and mediated miR-135a-induced
cell proliferation. In addition, p21, p27, Cyclin D1
and Ki67 were found to be dysregulated in miR-135a-
overexpressing bladder cancer cells, indicating a puta-
tive correlation between miR-135a and the PI3K/Akt
signaling pathway. Further studies are required to elu-
cidate the detailed molecular mechanism underlying
the role of miR-135a in tumor progression.Conclusion
This study shows that miR-135a is significantly upreg-
ulated and promotes cellular proliferation in bladder
cancer. The tumor suppressor genes, PHLPP2 and
FOXO1, are the direct targets of miR-135a and tran-
scriptionally downregulated by miR-135a. Suppression
of PHLPP2 or FOXO1, followed with dysregulation
of p21, p27, CyclinD1 and Ki67, play critical roles
during miR-135a-mediated bladder cancer cells pro-
liferation. MiR-135a functions as an onco-miR in
bladder cancer and interventions targeting miR-135a
may provide novel insights into approaches to bladder
cancer diagnosis and therapy.Additional files
Additional file 1: Figure S1. MiR-135a induces proliferation of BIU87
cells. A. Effects of miR-135a on proliferation of the indicated cells, as analyzed
by MTT assays. B. Representative micrographs (left) and quantifications (right)
of crystal violet stained colonies formed by the indicated cells. C. Effects of
miR-135a on the tumorigenicity of the indicated cells, as determined by
anchorage-independent growth ability assays. Bars represent the mean ±
SD of three independent experiments. *P <0.05.
Additional file 2: Figure S2. MiR-135a induces proliferation of bladder
cancer cells. A. Quantifications of crystal violet stained colonies formed by the
indicated cells. B. Effects of miR-135a on the tumorigenicity of the indicated
cells, as determined by anchorage-independent growth ability assays.
All these experiments were done with T24 and 5637 cells stably overexpressing
miR-135a, pMSCV-vector (presented as Vector) or non-transfected cell control
(presented as Blk). Bars represent the mean ± SD of three independent
experiments. *P <0.05.
Additional file 3: Figure S3. FOXO1 and PHLPP2 are direct targets of
miR-135a in bladder cancer cells. (A) Sequence of pGL3-FOXO1 or PHLPP2-3′
UTR reporter with a mutant miR-135a binding site. (B) Luciferase assay
of co-transfected with miR-135a or the control in the indicated cells.
Experiments were repeated at least 3 times with similar results, and error
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